- Home
- ITGR vs AKRO Comparison
ITGR vs AKRO Comparison
Compare ITGR & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITGR
- AKRO
- Stock Information
- Founded
- ITGR 1970
- AKRO 2017
- Country
- ITGR United States
- AKRO United States
- Employees
- ITGR N/A
- AKRO N/A
- Industry
- ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ITGR Health Care
- AKRO Health Care
- Exchange
- ITGR Nasdaq
- AKRO Nasdaq
- Market Cap
- ITGR 4.2B
- AKRO 3.9B
- IPO Year
- ITGR 2000
- AKRO 2019
- Fundamental
- Price
- ITGR $121.58
- AKRO $51.34
- Analyst Decision
- ITGR Strong Buy
- AKRO Strong Buy
- Analyst Count
- ITGR 10
- AKRO 6
- Target Price
- ITGR $145.90
- AKRO $82.50
- AVG Volume (30 Days)
- ITGR 434.3K
- AKRO 1.8M
- Earning Date
- ITGR 07-24-2025
- AKRO 08-08-2025
- Dividend Yield
- ITGR N/A
- AKRO N/A
- EPS Growth
- ITGR N/A
- AKRO N/A
- EPS
- ITGR 2.18
- AKRO N/A
- Revenue
- ITGR $1,746,192,000.00
- AKRO N/A
- Revenue This Year
- ITGR $11.03
- AKRO N/A
- Revenue Next Year
- ITGR $7.29
- AKRO N/A
- P/E Ratio
- ITGR $56.26
- AKRO N/A
- Revenue Growth
- ITGR 10.19
- AKRO N/A
- 52 Week Low
- ITGR $104.93
- AKRO $21.02
- 52 Week High
- ITGR $146.36
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ITGR 56.33
- AKRO 55.26
- Support Level
- ITGR $116.15
- AKRO $53.05
- Resistance Level
- ITGR $123.78
- AKRO $57.35
- Average True Range (ATR)
- ITGR 2.13
- AKRO 2.34
- MACD
- ITGR 0.37
- AKRO -0.51
- Stochastic Oscillator
- ITGR 76.80
- AKRO 35.75
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.